Corrective Phases R...
Health Care: Drugs
Dynavax Technologies Corporation (DVAX: NASDAQ)
$3.56 -0.05 | -1.38%
06/04/12 - 09:45 AM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 3.61 |
| 52 Week High | 5.34 |
| 52 Week Low | 1.75 |
| Avg. Daily Vol. (Mil) | 2.19 |
| Beta (3 year) | 2.45 |
| Share Related Items | |
| Mkt Cap (Mil) | 565.60 |
| Shares Out (Mil) | 156.68 |
| Float (Mil) | 97.23 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 4.20 |
| Current Ratio | 4.30 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.15 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 25.45 |
| Price/Book | 6.40 |
| Price/Cash Flow | -12.90 |
| Per Share Data | |
| Earnings | -0.34 |
| Sales | 0.14 |
| Book Value | 0.56 |
| Cash Flow | -0.28 |
| Business Summary | |
|---|---|
| Dynavax Technologies Corporation is a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases, asthma and inflammatory and autoimmune diseases. | |
| General Information | |
| 2929 Seventh Street
Suite 100 Berkeley, CA 94710-2722 |
|
| www.dynavax.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 150 | |
| CEO: Dr. Dino Dina,M.D. | |
| Short Interest | |
| Current Month (Mil) | 18.41 |
| Previous Month (Mil) | 19.97 |
| Short Interest Ratio (Days) | 6.30 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -38.60 |
| Return on Investments | -52.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with DVAX
- Portfolio NameUser Type
- Contributor10 Stocks Boosting Little F...
- UserMy stocks
- ContributorStocks Under-$10 Moving Hig...
- Contributor10 Stocks of Top-Performing...
- ContributorStocks At New 52-Week Highs...
- Contributor13 Biotech Stocks Bought an...
- Contributor10 Pharma Stocks Under $3
- Contributor4 Biotech Penny Stocks to Buy
- UserMy Portfolio
- UserStarters
Latest DVAX Headlines from TheStreet
- Dynavax Stock Gaps Down On Today's Open (DVAX) 05.09.12 | 09:05 am
- 10 Stocks Boosting Little Funds to Big Returns (Update2) 03.16.12 | 02:03 pm
- 8 Stocks Under $10 Moving Higher 02.02.12 | 02:02 pm
- 10 Stocks of Top-Performing Funds in 2012 01.20.12 | 10:01 am
- Biotech Calendar: Key Dates for October 10.03.11 | 08:10 am
- Biotech Calendar: Key Dates for September 08.31.11 | 06:08 am
- Dynavax Stock Gaps Down On Today's Open (DVAX) 07.20.11 | 09:07 am
- 10 Pharma Stocks Under $3 06.16.11 | 01:06 pm
- 4 Biotech Penny Stocks to Buy: Navellier 04.13.11 | 11:04 am
- Dynavax, Frontier Financial: Early Volume Plays 04.27.10 | 07:04 am
Press Releases for DVAX
Partner Headlines for DVAX
- Company News for May 10, 2012 - Corporate Summary - Zacks 05.10.12 | 10:05 am
- Buy And Sell Ideas Based On Monday's Big Biotech News Movers - Seeking Alpha 10.11.11 | 08:10 am
- Dynavax Reports Diabetic Subset Data From Modified Intent to Treat Analysis of the HEPLISAV Phase 3 Trial - Benzinga 10.06.11 | 04:10 pm
- 7 Breakout Stocks With Sufficient Cash to Cover Operating Expenses - Seeking Alpha 03.29.11 | 08:03 am
- Data from Dynavax for HBV Candidate - Analyst Blog - Zacks 12.27.10 | 01:12 pm
- Dynavax Announces $30 Million Common Stock Purchase (DVAX) - Benzinga 09.20.10 | 04:09 pm
- UPDATE 1-Dynavax posts Q2 loss, shares fall - Reuters 07.30.10 | 05:07 pm
- UPDATE 1-Dynavax's flu vaccine shows promise, shares rise - Reuters 04.26.10 | 05:04 pm
- Healthcare, Technology Converge: Recent Biotech Deals - SeekingAlpha.com 04.19.10 | 05:04 am
- UPDATE 1-Dynavax hep B vaccine shows promise in kidney disease - Reuters 04.14.10 | 05:04 pm
